Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 Topline data from par
Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 Topline data from par